Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Purpose Provide 2-year efficacy, safety and treatment results comparing three anti-vascular endothelial growth factor (anti-VEGF) agents for center-involved diabetic macular edema (DME) utilizing a standardized follow-up and retreatment regimen. Design Randomized clinical trial. Participants 660 participants with DME causing visual acuity (VA) impairment. Methods Randomization to 2.0-mg aflibercept, 1.25-mg repackaged (compounded) bevacizumab, or 0.3-mg ranibizumab intravitreous injections performed as frequently as monthly utilizing a protocol-specific follow-up and retreatment regimen. Focal/grid laser was added if DME persisted and was not improving at 6 months or later. Visits occurred every 4 weeks during year 1, and were extended up to every 4 months thereafter when VA and macular thickness were stable and injections were deferred. Main Outcome Measures Change in VA (efficacy), ocular/systemic adverse events (safety), retreatment frequency. Results Median numbers of injections in year 2 were 5, 6, 6 and over 2 years were 15, 16, 15 in the aflibercept, bevacizumab, and ranibizumab groups, respectively (global P=0.08). Focal/grid laser was administered in 41%, 64%, and 52%, respectively (aflibercept-bevacizumab: P<0.001, aflibercept-ranibizumab: P=0.04, bevacizumab-ranibizumab: P=0.01). From baseline to 2 years, mean VA letter score improved by 12.8 with aflibercept, 10.0 with bevacizumab, and 12.3 with ranibizumab. Treatment group differences varied by baseline VA (interaction P=0.02). With worse baseline VA (20/50-20/320), mean improvement was 18.3, 13.3, and 16.1 letters, respectively (aflibercept-bevacizumab: P=0.02, aflibercept-ranibizumab: P=0.18, ranibizumab-bevacizumab: P=0.18). With baseline VA 20/32-20/40, mean improvement was 7.8, 6.8, and 8.6 letters, respectively (P>0.10 for pairwise comparisons). Anti-Platelet Trialists’ Collaboration (APTC) events occurred in 5% with aflibercept, 8% with bevacizumab, and 12% with ranibizumab (global P=0.047: aflibercept-bevacizumab: P=0.34, aflibercept-ranibizumab: P=0.047, ranibizumab-bevacizumab: P=0.20; global P=0.09 adjusted for potential confounders). Conclusion All 3 anti-VEGF groups had visual acuity improvement at 2 years with a decreased number of injections in year 2. VA outcomes were similar among treatment groups for eyes with baseline VA 20/32-20/40. Among eyes with worse baseline VA, aflibercept, on average, had superior 2-year VA outcomes compared with bevacizumab, but superiority of aflibercept over ranibizumab, noted at 1 year, was no longer identified. Higher APTC event rates with ranibizumab over 2 years warrants continued evaluation in future trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
De Cillà, S. D., Farruggio, S., Vujosevic, S., Raina, G., Filippini, D., Gatti, V., Clemente, N., Mary, D., Vezzola, D., Casini, G., et al. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479441 · Cited by 5,136
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Schafer, J. L. (1999) · Statistical Methods in Medical Research · doi:10.1177/096228029900800102 · Cited by 3,949
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
Antiplatelet Trialists' Collaboration (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 3,126
Easy SAS Calculations for Risk or Prevalence Ratios and Differences
Spiegelman, D. (2005) · American Journal of Epidemiology · doi:10.1093/aje/kwi188 · Cited by 1,738
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
Martin, D. F., Maguire, M. G., Fine, S. L., Ying, G.-S., Jaffe, G. J., Grunwald, J. E., Toth, C., Redford, M., & Ferris, F. L. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.03.053 · Cited by 1,715
Self-citationRanibizumab for Diabetic Macular Edema
Nguyen, Q. D., Brown, D. M., Marcus, D. M., Boyer, D. S., Patel, S., Feiner, L., Gibson, A., Sy, J., Rundle, A. C., Hopkins, J. J., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2011.12.039 · Cited by 1,621
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
The Diabetic Retinopathy Clinical Research Network (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414264 · Cited by 1,607
Elman, M. J., Aiello, L. P., Beck, R. W., Bressler, N. M., Bressler, S. B., Edwards, A. R., Ferris, F. L., Friedman, S. M., Glassman, A. R., Miller, K. M., et al. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2010.02.031 · Cited by 1,428
Self-citation
Cited by
Optical coherence tomography angiography
Spaide, R. F., Fujimoto, J. G., Waheed, N. K., Sadda, S. R., & Staurenghi, G. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.11.003 · Cited by 1,779
Diabetic Retinopathy: Pathophysiology and Treatments
Wang, W., & Lo, A. C. Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061816 · Cited by 1,358
Diabetic retinopathy: current understanding, mechanisms, and treatment strategies
Duh, E. J., Sun, J. K., & Stitt, A. W. (2017) · JCI Insight · doi:10.1172/jci.insight.93751 · Cited by 1,057
Diabetic Retinopathy Preferred Practice Pattern®
Flaxel, C. J., Adelman, R. A., Bailey, S. T., Fawzi, A., Lim, J. I., Vemulakonda, G. A., & Ying, G.-S. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2019.09.025 · Cited by 717
Schmidt-Erfurth, U., Garcia-Arumi, J., Bandello, F., Berg, K., Chakravarthy, U., Gerendas, B. S., Jonas, J., Larsen, M., Tadayoni, R., & Loewenstein, A. (2017) · Ophthalmologica · doi:10.1159/000458539 · Cited by 703
Diabetic retinopathy: Looking forward to 2030
Tan, T.-E., & Wong, T. Y. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1077669 · Cited by 511
Update in the epidemiology, risk factors, screening, and treatment of diabetic retinopathy
Lin, K., Hsih, W., Lin, Y., Wen, C., & Chang, T. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13480 · Cited by 446
Microvascular Dysfunction in Diabetes Mellitus and Cardiometabolic Disease
Horton, W. B., & Barrett, E. J. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnaa025 · Cited by 424
Diabetic Macular Edema Pathophysiology: Vasogenic versus Inflammatory
Romero-Aroca, P., Baget-Bernaldiz, M., Pareja-Rios, A., Lopez-Galvez, M., Navarro-Gil, R., & Verges, R. (2016) · Journal of Diabetes Research · doi:10.1155/2016/2156273 · Cited by 404
Tan, G. S., Cheung, N., Simó, R., Cheung, G. C. M., & Wong, T. Y. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30052-3 · Cited by 361
VEGFR1 signaling in retinal angiogenesis and microinflammation
Uemura, A., Fruttiger, M., D'Amore, P. A., De Falco, S., Joussen, A. M., Sennlaub, F., Brunck, L. R., Johnson, K. T., Lambrou, G. N., Rittenhouse, K. D., et al. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.100954 · Cited by 354
Avery, R. L., Castellarin, A. A., Steinle, N. C., Dhoot, D. S., Pieramici, D. J., See, R., Couvillion, S., Nasir, M. A., Rabena, M. D., Maia, M., et al. (2017) · Retina · doi:10.1097/iae.0000000000001493 · Cited by 352
Bressler, N. M., Beaulieu, W. T., Glassman, A. R., Blinder, K. J., Bressler, S. B., Jampol, L. M., Melia, M., Wells, J. A., & for the Diabetic Retinopathy Clinical Research Network (2018) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2017.6565 · Cited by 343
Self-citationAngiogenesis and Inflammation Crosstalk in Diabetic Retinopathy
Capitão, M., & Soares, R. (2016) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25575 · Cited by 312
Baker, C. W., Glassman, A. R., Beaulieu, W. T., Antoszyk, A. N., Browning, D. J., Chalam, K. V., Grover, S., Jampol, L. M., Jhaveri, C. D., Melia, M., et al. (2019) · JAMA · doi:10.1001/jama.2019.5790 · Cited by 299
Self-citationJoussen, A. M., Ricci, F., Paris, L. P., Korn, C., Quezada-Ruiz, C., & Zarbin, M. (2021) · Eye · doi:10.1038/s41433-020-01377-x · Cited by 290
Sahni, J., Patel, S. S., Dugel, P. U., Khanani, A. M., Jhaveri, C. D., Wykoff, C. C., Hershberger, V. S., Pauly-Evers, M., Sadikhov, S., Szczesny, P., et al. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2019.03.023 · Cited by 285
Self-citationVaradarajan, A. V., Bavishi, P., Ruamviboonsuk, P., Chotcomwongse, P., Venugopalan, S., Narayanaswamy, A., Cuadros, J., Kanai, K., Bresnick, G., Tadarati, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13922-8 · Cited by 139
Jani, P. D., Forbes, L., Choudhury, A., Preisser, J. S., Viera, A. J., & Garg, S. (2017) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2017.1150 · Cited by 127
Melo, G. B., Cruz, N. F. S. D., Emerson, G. G., Rezende, F. A., Meyer, C. H., Uchiyama, S., Carpenter, J., Shiroma, H. F., Farah, M. E., Maia, M., et al. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100862 · Cited by 114
Suprachoroidal CLS-TA plus Intravitreal Aflibercept for Diabetic Macular Edema
Barakat, M. R., Wykoff, C. C., Gonzalez, V., Hu, A., Marcus, D., Zavaleta, E., & Ciulla, T. A. (2021) · Ophthalmology Retina · doi:10.1016/j.oret.2020.08.007 · Cited by 55
Melo, G. B., Figueira, A. C. M., Batista, F. A. H., Filho, A. A. S. L., Rodrigues, E. B., Belfort, R., & Maia, M. (2019) · Ophthalmic Surgery, Lasers and Imaging Retina · doi:10.3928/23258160-20190503-05 · Cited by 51
Release of silicone oil droplets from syringes
Melo, G. B., Dias Junior, C. D. S., Carvalho, M. R., Cardoso, A. L., Morais, F. B., Figueira, A. C. M., Lima Filho, A. A. S., Emerson, G. G., & Maia, M. (2019) · International Journal of Retina and Vitreous · doi:10.1186/s40942-018-0153-8 · Cited by 50
Patel, D., Ananthakrishnan, A., Lin, T., Channa, R., Liu, T. Y. A., & Wolf, R. M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11237120 · Cited by 43
Gene-based therapeutics for acquired retinal disease: opportunities and progress
Tan, T.-E., Fenner, B. J., Barathi, V. A., Tun, S. B. B., Wey, Y. S., Tsai, A. S. H., Su, X., Lee, S. Y., Cheung, C. M. G., Wong, T. Y., et al. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.795010 · Cited by 26
New frontiers of retinal therapeutic intervention: a critical analysis of novel approaches
Nanegrungsunk, O., Au, A., Sarraf, D., & Sadda, S. R. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2066169 · Cited by 20
Fu, D. J., Mishra, A. V., Quek, C., Balaskas, K., Pontikos, N., Sim, D., Sivaprasad, S., & Faes, L. (2025) · Eye · doi:10.1038/s41433-024-03529-9 · Cited by 14
Hertzberg, S. N. W., Jørstad, Ø. K., Petrovski, B. É., Bragadottir, R., Steffensen, L. A., Moe, M. C., Burger, E. A., & Petrovski, G. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph191912603 · Cited by 6
Metadata
- Authors
- Wells, J. A., Glassman, A. R., Ayala, A. R., Jampol, L. M., Bressler, N. M., Bressler, S. B., Brucker, A. J., Ferris, F. L., Hampton, G. R., Jhaveri, C., Melia, M., & Beck, R. W.
- Venue
- Ophthalmology
- Publisher
- Elsevier BV
- Published
- 2016-06
- Volume
- 123
- Issue
- 6
- Pages
- 1351-1359
- ISSN
- 0161-6420 (ISSN-L)
- OpenAlex
- W2289200040
- Cited by
- 1,051
- References
- 16
- FWCI
- 104.55
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.